Nice post Ecomike- I knew Larry, the MVTG founder and CEO

New Post Public Reply Private Reply Replies (1) Message Board
Silver Boy
Nice post Ecomike-
I knew Larry, the MVTG founder and CEO with a vision, when and before MVTG was nearly dead, nearly lights out in Dec 2011, when things looked like they might not survive due to the world financial crisis US Congress was threatening default on US Debt) and rampant fear was loose in the market place (kinda like the recent Grexit but on a much larger scale). MVTG had no issued patents yet. No significant anti dilution investments were to be found. And Larry refused to use toxic debt financing.

The stock price had crashed to .01 and even to .0047 intraday, and I had already bought shares between .21 and .07 and in a one minute in dec 2011, a 250,000 share 1 minute dump by a dying cancer patient that was an early MVTG IPO investor crashed the price from .07 to .0047 and then it settled at .01 that day.

I and friends and family of mine bought all the MVTG shares we could at under .02 after that event.

Best investment I ever made.

Not long after that MVTG rallied to .08 then to .12 then .20 and then .30 in 2012. At that time I was up 3000%, but like today and the last 6 years I did not sell. I am in this for the long haul, the move to $5 to $10/share prices, like my other past picks have done. For example Mhan was at .001 that I bought the bottom on for 2 years, that is now near $19/share as Tgtx, another start up like MVTG with no sales. A biotech with less than MVTG has right now, except they have already uplisted like MVTG is planning to do to Nasdaq. Al they have is huge R&D costs for 10 years ahead of them and issued patents like MVTG

In 2014 MVTG rallied from .047/.06 (I got lucky and scored all the .06 shares at the bottom that day) to .75/.74 in three huge million share trade per day rallies. MVTG has a history of these rallies and is still in a 4 year long term rally to higher lows and higher highs.

New shares to fund MVTG were sold at prices as high as .40/share in 2014, $700,000 worth bought by old time private placement investors that had bought at .08 to .20 and they had options to buy more at .40, they bought all those options in 2014 at .40 not much over 12 months ago!!!!!

They bought restricted shares at .40!!!!! So these low prices today are screaming bargains right now, as MVTG has far more now to offer than they did then. MVTG now has the ERC patent issued in Canada and the MRFC fuel cell patent issued in the USA since the .40 shares were bought. Retail payed as much as .74/.75 on three rallies before these added assets were added to the MVTG success list. The $749,000 in Canadian grants have been added since then.

The Bavarian Germany brewery ERC-pilot plant has been added to the MVTG success list since then.

Completing the phase 2 and starting phase 3 of the MVTG-Alstom R&D revenue project has happened since then. That means MVTG is worth way more than .75/share now!!!!!

That means Alstom liked the R&D catalyst research results of Phase 2, as in it works for making syn gas so well that Alstom funded phase 3 and started phase 3!!!!

Phase three is just a plant design and costing exercise that should be entering phase 4 shortly. Phase 5 would be the beginning of an Alstom funded Pilot plant, maybe the German plant or a third Pilot plant (US DOE-Alston coal???) or both???

MVTG has since then (the low of Dec 2011) scored 6 issued patents,

5 more applied for in 2013 that are about to be published in print for all to see and read.

And MVTG has applied for many more patents as they mentioned in the recent PRs.

MVTG has received substantial funding from Alstom tied to their patents and the ERC technology.

MVTG has two ERC pilot plant agreements in place, one in Canada and one brand new one in Germany

MVTG has received over $749,000 in recent Canadian agency government grants. $449,000 in just one 2 year R&D grant. That is about 50 times the grant funding MVTG received since the 2008 IPO!!!!! Received just this year. Add in the nearly 1 million dollars that Alstom has already committed to MVTG and the 5-10 million Alstom could commit to in Phase 5 later this year and you have no excuse for not buying up these cheap MVTGs shares with spare cash.

I am buying more MVTG. I have been through far worse times with MVTG. My faith in MVTG and the CEO is not shaken one bit!!!!

High Wire Networks Inc. (HWNI) Stock Research Links

HWNI Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

HONA Faces Legal Heat: Investor Lawsuit Over Losses

Updated Category News Views 5

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 4

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading
Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Updated Category News Views 3

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 2

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 4

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading
Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 2

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 3

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 4

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Dynamics of Texas Instruments' Short Interest

Updated Category News Views 124

Delving into the Short Interest of Texas Instruments Texas Instruments TXN has recently seen a notable decrease in its short interest, which has fallen by 12.71% since the last report. As of the latest figures, the company reported that approximately 16.83 million shares have been sold short, representing around 2.06% of all shares available for trading. With these...

Continue Reading
Nuvoton Launches Revolutionary 1.7W Indigo Laser Diode

Updated Category News Views 343

Nuvoton Introduces an Innovative Indigo Laser Diode Nuvoton Technology Corporation Japan, widely known as NTCJ, has celebrated another milestone in laser technology with the introduction of their groundbreaking indigo semiconductor laser. This innovative product boasts an impressive optical output power of 1.7 W and operates at a wavelength of 420 nm, making it a...

Continue Reading
Exploring the Surge in Japanese Stocks Amid Political Changes

Updated Category News Views 121

Japanese Stocks Reach New Heights In recent times, Japanese stocks have soared to impressive new highs, buoyed by a combination of economic factors and political dynamics. A notable factor in this surge has been a weakening yen, coupled with increasing bond yields, coinciding with discussions around potential snap elections initiated by Prime Minister Sanae Takaichi....

Continue Reading
TGS Enhances Summer Operations in Northern Europe with Vessels

Updated Category News Views 183

TGS Expands Summer Operations in Northern Europe TGS, a renowned provider of energy data and intelligence, has reported an exciting summer season ahead in Northern Europe. This year, the company has not only increased its acquisition capacity but has also enhanced its operational efficiency with the deployment of four acquisition vessels in the region: three seismic...

Continue Reading
Zentalis Pharmaceuticals Welcomes James B. Bucher as CLO

Updated Category News Views 152

Zentalis Pharmaceuticals Strengthens Leadership with New Appointment In a significant move, Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company focused on innovative therapies for cancer treatment, is thrilled to announce the appointment of James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary. This strategic step comes...

Continue Reading